
ENTX Stock Forecast & Price Target
ENTX Analyst Ratings
Bulls say
Entera Bio is a promising company with a potential blockbuster drug, EB613, in development for postmenopausal osteoporosis, and other programs utilizing their N-Tab platform for oral peptide delivery. With a BUY rating and projected annual sales of $1.1Bn by 2040, Entera Bio's oral administration of drugs is seen as advantageous and may lead to better results. The company's experienced CEO is also involved in developing another oral tablet, EB618, for treating obesity, further demonstrating their expertise in the biotech industry.
Bears say
Entera Bio is still in the early stages of product development and may face challenges in obtaining FDA approval and gaining market acceptance. The company's current financial status is also a cause for concern, with significant losses reported in recent years. Additionally, the biopharmaceutical industry is highly competitive, and the success of ENTX's products will ultimately depend on their ability to differentiate themselves from other treatments in the market and gain market share.
This aggregate rating is based on analysts' research of Entera Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.
ENTX Analyst Forecast & Price Prediction
Start investing in ENTX
Order type
Buy in
Order amount
Est. shares
0 shares